Poolbeg Pharma Ltd. (7JN) Price & Analysis

1 Followers

7JN Stock Chart & Stats

€0.08

€0.00(0.00%)

At close: Jul 29 4:00 PM EDT

€0.08

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.03 - €0.11

Previous CloseN/A

Volume0.00

Average Volume (3M)5.00

Market Cap

€62.23M

Enterprise Value€43.38M

Total Cash (Recent Filing)€4.82M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Mar 04, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding763,437,130

10 Day Avg. Volume16

30 Day Avg. Volume5

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)2.80

Price to Sales (P/S)0.00

P/FCF Ratio-4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Regulatory ProgressRegulatory approval, finalized execution plans, selected sites, and CRO support reduce development friction and enable a near-term clinical readout. This advances POLB 001 from experimental preparation toward patient evidence, creating a clearer basis for partnering and future asset monetization.

Strong Early Target EngagementThe dose response and substantial cytokine suppression provide encouraging proof of biological activity for POLB 001. If the signal translates into the target cancer setting, it could support differentiation, improve partnering leverage, and reduce scientific uncertainty around continued development.

Long-duration Intellectual PropertyPatent coverage extending to at least 2044 could protect the commercial opportunity over a prolonged period if clinical development succeeds. Durable exclusivity supports potential licensing value, preserves strategic flexibility, and gives future partners time to recover development and commercialization costs.

Bears Say

Pre-revenue Loss ProfileThe absence of commercial revenue means Poolbeg currently depends on development funding rather than operating sales to sustain its business. Persistent losses also show that earnings power is unproven, leaving future financial performance highly dependent on clinical success and eventual partnering or licensing income.

Persistent Cash ConsumptionSustained operating and free-cash-flow outflows consume resources while the pipeline remains in development. Continued cash use increases dependence on future fundraising, grants, or licensing transactions, and can constrain the pace of trials if external capital or partners are not secured on acceptable terms.

Limited Clinical Evidence DesignA small, uncontrolled and unblinded study may detect an initial signal but cannot establish definitive efficacy with the same confidence as a randomized controlled trial. Ambiguous results could require additional studies, extending timelines, increasing funding needs, and delaying partner decisions or commercialization.

Poolbeg Pharma Ltd. News

Poolbeg bolsters POLB 001 patent protection with South Korean grant

An update from Poolbeg Pharma Ltd. ( ($GB:POLB) ) is now available. Poolbeg Pharma has secured a South...

7d ago

Poolbeg Pharma advances POLB 001 and extends cash runway with 2026 interim results

The latest update is out from Poolbeg Pharma Ltd. ( ($GB:POLB) ). Poolbeg Pharma reported interim results for...

14d ago

Poolbeg advances POLB 001 CRS trial with steady patient recruitment

Poolbeg Pharma Ltd. ( ($GB:POLB) ) just unveiled an update. Poolbeg Pharma said recruitment in its POLB 001...

15d ago

Poolbeg cleared to press ahead with POLB 001 trial after positive safety review

Poolbeg Pharma Ltd. ( ($GB:POLB) ) has provided an announcement. Poolbeg Pharma has reported positive interim safety data...

19d ago

Poolbeg Pharma to spotlight POLB 001 at global scientific and investor conferences

Poolbeg Pharma Ltd. ( ($GB:POLB) ) has issued an update. Poolbeg Pharma will showcase its lead cancer immunotherapy-support...

1M ago

Poolbeg Pharma Wins Israeli Patent Allowance for Key Cancer Immunotherapy Asset

An announcement from Poolbeg Pharma Ltd. ( ($GB:POLB) ) is now available. Poolbeg Pharma has received a Notice...

3M ago

Poolbeg Pharma raises £3.5m to fund key cancer and obesity trials

Poolbeg Pharma Ltd. ( ($GB:POLB) ) has shared an update. Poolbeg Pharma has raised £3.5 million via a...

3M ago

Poolbeg Pharma Begins POLB 001 Trial, Targets Major CRS Market Opportunity

Poolbeg Pharma Ltd. ( ($GB:POLB) ) just unveiled an update. Poolbeg Pharma has dosed the first patient in...

3M ago

Poolbeg Pharma strengthens POLB 001 patent protection in South Africa

The latest announcement is out from Poolbeg Pharma Ltd. ( ($GB:POLB) ). Poolbeg Pharma has secured a patent...

3M ago

Poolbeg Wins Key European Patent for Lead Cancer Immunotherapy Asset

An announcement from Poolbeg Pharma Ltd. ( ($GB:POLB) ) is now available. Poolbeg Pharma has secured a decision...

4M ago

7JN FAQ

What was Poolbeg Pharma Ltd.’s price range in the past 12 months?

Poolbeg Pharma Ltd. lowest stock price was €0.03 and its highest was €0.11 in the past 12 months.

What is Poolbeg Pharma Ltd.’s market cap?

Poolbeg Pharma Ltd.’s market cap is €62.23M.

When is Poolbeg Pharma Ltd.’s upcoming earnings report date?

Poolbeg Pharma Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 143 days.

How were Poolbeg Pharma Ltd.’s earnings last quarter?

Poolbeg Pharma Ltd. released its earnings results on Sep 29, 2026. The company reported -€0.004 earnings per share for the quarter.

Is Poolbeg Pharma Ltd. overvalued?

According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Poolbeg Pharma Ltd. pay dividends?

Poolbeg Pharma Ltd. does not currently pay dividends.

What is Poolbeg Pharma Ltd.’s EPS estimate?

Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Poolbeg Pharma Ltd. have?

Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.

What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?

Poolbeg Pharma Ltd. reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went up 5.714%.

Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?

Currently, no hedge funds are holding shares in DE:7JN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Poolbeg Pharma Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-71.28%

Trailing 12-Months

Asset Growth

-42.16%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Poolbeg Pharma Ltd.

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.